MRI在三阴性乳腺癌新辅助化疗疗效评价中的研究进展OA北大核心CSTPCD

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by high heterogeneity and aggressiveness. Because of the absence of effective therapeutic targets,TNBC is insensitive to endocrine therapy and targeted therapy,resulting in a poor prognosis. Currently,neoadjuvant chemotherapy (NAC) is one of the standard treatment strategies for TNBC. Given the individual variances and tumor heterogeneity,TNBC patients' response to NAC varies significantly,leading to diverse treatment outcomes. Therefore,early and accurate assessment of NAC efficacy is crucial for formulating subsequent treatment plans and predicting prognosis for TNBC patients. Magnetic resonance imaging (MRI) is widely utilized for monitoring the effectiveness of tumor treatment due to its high resolution for soft tissue and quantitative imaging technology,enabling accurate depiction of changes in tumor parenchyma and its microenvironment. MRI-based radiomics can deeply explore the imaging characteristics of TNBC before and after NAC,providing more comprehensive tumor information for evaluating NAC efficacy. In recent years,researchers both domestically and internationally have conducted extensive studies on the evaluation of NAC efficacy in TNBC using radiomics. This article aims to review the clinical applications and research advancements of MRI in assessing the efficacy of NAC in TNBC patients,with the goal of providing insights for developing precise and personalized treatment approaches for these patients.